College of Behavioral and Community Science, Department of Mental Health Law and Policy, University of South Florida, Tampa, FL, USA.
Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, IL, USA.
Am J Drug Alcohol Abuse. 2021 Mar 4;47(2):220-228. doi: 10.1080/00952990.2020.1824236. Epub 2020 Oct 15.
: A cascade of care (CoC) model may improve understanding of gaps in addiction treatment availability and quality over current single measure methods. Despite increased funding, opioid overdose rates remain high. Therefore, it is critical to understand where the health-care system is failing to provide appropriate care for people with opioid use disorder (OUD) diagnoses, and to assess disparities in receipt of medication for OUD (MOUD).: Using a CoC framework, assess treatment quality and outcomes for OUD in the Florida Medicaid population in 2017/2018 by demographics and primary vs. secondary diagnosis.: Data from Florida Medicaid claims for 2017 and 2018 were used to calculate the number of enrollees who were diagnosed, began MOUD, were retained on medication for a minimum of 180 days, and who died.: Only 28% of those diagnosed with OUD began treatment with an FDA approved MOUD (buprenorphine, methadone, or injectable naltrexone). Once on medication, 38% of newly diagnosed enrollees were retained in treatment for180 days. Those who remained on MOUD for 180 days had a hazard ratio of death of 0.226 (95% CI = 0.174 to 0.294) compared to those that did not initiate MOUD, a reduction in mortality from 10% without MOUD to 2% with MOUD.: Initiating medication after OUD diagnosis offers the greatest opportunity for intervention to reduce overdose deaths, though efforts to increase retention are also warranted. Analyzing claims data with CoC identifies system functioning for specific populations, and suggests policies and clinical pathways to target for improvement.
: 级联护理 (CoC) 模型可能有助于了解当前单一措施方法中在成瘾治疗可及性和质量方面存在的差距。尽管资金增加,但阿片类药物过量率仍然很高。因此,了解医疗保健系统在为患有阿片类药物使用障碍 (OUD) 诊断的人提供适当护理方面存在哪些不足,并评估接受 OUD 药物治疗 (MOUD) 的差异至关重要。: 使用 CoC 框架,按人口统计学和主要与次要诊断评估 2017/2018 年佛罗里达州医疗补助人群中 OUD 的治疗质量和结果。: 2017 年和 2018 年佛罗里达州医疗补助索赔数据用于计算被诊断患有 OUD、开始接受 MOUD 治疗、至少接受 180 天药物治疗以及死亡的参保人数。: 只有 28%被诊断患有 OUD 的人开始接受 FDA 批准的 MOUD(丁丙诺啡、美沙酮或注射用纳曲酮)治疗。一旦开始用药,新诊断参保者中有 38%在治疗中保留了 180 天。在 180 天内接受 MOUD 治疗的患者的死亡风险比未开始 MOUD 治疗的患者低 0.226(95%CI=0.174 至 0.294),死亡率从无 MOUD 治疗的 10%降至有 MOUD 治疗的 2%。: 在 OUD 诊断后开始使用药物治疗为减少过量死亡提供了最大的干预机会,但也需要努力提高保留率。使用 CoC 分析索赔数据可确定特定人群的系统功能,并提出有针对性的政策和临床途径以进行改进。